by Teresa Carroll | News and Updates
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and... by Teresa Carroll | News and Updates
Erva Bayraktar, Ph.D. was recently awarded the Peripheral Nerve Society’s Laura Feltri Basic Science Fellowship at its annual meeting, held in May in Edinburgh, Scotland. This prestigious grant provides two years of funding to allow a junior scientist to... by Teresa Carroll | News and Updates
In a TIN-sponsored study newly published in the May issue of Neuromuscular Disorders (https://doi.org/10.1016/j.nmd.2025.105345) the Martini group now reports that CMT1X mice treated with Fingolimod showed improved nerve function, and the drug positively changed some... by Teresa Carroll | Physical Therapy
How Charcot Marie Tooth Disease Affects Balance & How TIN’s Physical Therapy Videos Can Help! When you live with an inherited neuropathy like Charcot-Marie-Tooth Disease (CMT) every day, you soon understand the effect this neuromuscular condition has on the... by Teresa Carroll | News and Updates
The sponsor of the study is NMD Pharma A/S. If you’re living with Charcot-Marie-Tooth (CMT) disease, specifically CMT1 or CMT2 subtypes you may be eligible to participate in an exciting new clinical trial. NMD Pharma, a biotechnology company, has received approval... 
